Cancer R&D tips the scales at the FDA as active INDs climb to record high
The FDA periodically likes to give itself a high grade as a top performer. And like any good bureaucracy, it has the numbers to back itself up. But a new presentation by Patrick Frey, the chief of staff in the Office of New Drugs at the agency, has come up with a series of slides that also underscores some important trends in drug R&D.
One of the top snapshots in the slide show highlights a key fact. As of the end of November, active INDs hit 7,020 — and that’s a 14-year high signifying a steady growth since 2004, when the number was 4,361.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.